Zinc supplementation increases procollagen type 1 amino-terminal propeptide in premenarcheal girls: A randomized controlled trial

Paige K. Berger, Norman K. Pollock, Emma M. Laing, Valerie Chertin, Paul J. Bernard, Arthur Grider, Sue A. Shapses, Kehong Ding, Carlos M Isales, Richard D. Lewis

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background: Data have shown that healthy children and adolescents have an inadequate intake of zinc, an essential nutrient for growth. It is unclear whether zinc supplementation can enhance bone health during this rapid period of growth and development. Objective: The primary aim of this study was to determine the effect of zinc supplementation on biochemical markers of bone turnover and growth in girls entering the early stages of puberty. The secondary aim was to test moderation by race, body mass index (BMI) classification, and plasma zinc status at baseline. Methods: One hundred forty seven girls aged 9-11 y (46% black) were randomly assigned to a daily oral zinc tablet (9 mg elemental zinc; n = 75) or an identical placebo (n = 72) for 4 wk. Fasting plasma zinc, procollagen type 1 amino-terminal propeptide (P1NP; a bone formation marker), carboxy-terminal telopeptide region of type 1 collagen (ICTP; a bone resorption marker), and insulin-like growth factor I (IGF-I) were assessed at baseline and post-test. Additional markers of bone formation (osteocalcin) and resorption (urinary pyridinoline and deoxypyridinoline) were also measured. Results: Four weeks of zinc supplementation increased plasma zinc concentrations compared with placebo [mean change, 1.8 μmol/L (95% CI: 1.0, 2.6) compared with 0.2 μmol/L (95% CI: 20.3, 0.7); P < 0.01]. Zinc supplementation also increased serum P1NP concentrations compared with placebo [mean change, 23.8 μmol/L (95% CI: 214.9, 62.5) compared with 231.0 μmol/L (95% CI: 266.4, 4.2); P = 0.04). There was no effect from zinc supplementation on osteocalcin, ICTP, pyridinoline, deoxypyridinoline, or IGF-I. There was no moderation by race, BMI classification, or plasma zinc status at baseline. Conclusions: Our data suggest that 4 wk of zinc supplementation increases bone formation in premenarcheal girls. Further studies are needed to determine whether supplemental zinc can improve childhood bone strength. This trial was registered at clinicaltrials.gov as NCT01892098.

Original languageEnglish (US)
Pages (from-to)2699-2704
Number of pages6
JournalJournal of Nutrition
Volume145
Issue number12
DOIs
StatePublished - Jan 1 2015

Fingerprint

Collagen Type I
Zinc
Randomized Controlled Trials
Osteogenesis
Osteocalcin
Placebos
Bone Resorption
Insulin-Like Growth Factor I
Body Mass Index
Bone and Bones
Bone Remodeling
Bone Development
Puberty
Growth and Development
Tablets
Fasting
Biomarkers

Keywords

  • Bone
  • Bone turnover
  • Children
  • Growth
  • Zinc

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Nutrition and Dietetics

Cite this

Zinc supplementation increases procollagen type 1 amino-terminal propeptide in premenarcheal girls : A randomized controlled trial. / Berger, Paige K.; Pollock, Norman K.; Laing, Emma M.; Chertin, Valerie; Bernard, Paul J.; Grider, Arthur; Shapses, Sue A.; Ding, Kehong; Isales, Carlos M; Lewis, Richard D.

In: Journal of Nutrition, Vol. 145, No. 12, 01.01.2015, p. 2699-2704.

Research output: Contribution to journalArticle

Berger, Paige K. ; Pollock, Norman K. ; Laing, Emma M. ; Chertin, Valerie ; Bernard, Paul J. ; Grider, Arthur ; Shapses, Sue A. ; Ding, Kehong ; Isales, Carlos M ; Lewis, Richard D. / Zinc supplementation increases procollagen type 1 amino-terminal propeptide in premenarcheal girls : A randomized controlled trial. In: Journal of Nutrition. 2015 ; Vol. 145, No. 12. pp. 2699-2704.
@article{c2d9eef412ee41a3bb26dcf5d9eef8ee,
title = "Zinc supplementation increases procollagen type 1 amino-terminal propeptide in premenarcheal girls: A randomized controlled trial",
abstract = "Background: Data have shown that healthy children and adolescents have an inadequate intake of zinc, an essential nutrient for growth. It is unclear whether zinc supplementation can enhance bone health during this rapid period of growth and development. Objective: The primary aim of this study was to determine the effect of zinc supplementation on biochemical markers of bone turnover and growth in girls entering the early stages of puberty. The secondary aim was to test moderation by race, body mass index (BMI) classification, and plasma zinc status at baseline. Methods: One hundred forty seven girls aged 9-11 y (46{\%} black) were randomly assigned to a daily oral zinc tablet (9 mg elemental zinc; n = 75) or an identical placebo (n = 72) for 4 wk. Fasting plasma zinc, procollagen type 1 amino-terminal propeptide (P1NP; a bone formation marker), carboxy-terminal telopeptide region of type 1 collagen (ICTP; a bone resorption marker), and insulin-like growth factor I (IGF-I) were assessed at baseline and post-test. Additional markers of bone formation (osteocalcin) and resorption (urinary pyridinoline and deoxypyridinoline) were also measured. Results: Four weeks of zinc supplementation increased plasma zinc concentrations compared with placebo [mean change, 1.8 μmol/L (95{\%} CI: 1.0, 2.6) compared with 0.2 μmol/L (95{\%} CI: 20.3, 0.7); P < 0.01]. Zinc supplementation also increased serum P1NP concentrations compared with placebo [mean change, 23.8 μmol/L (95{\%} CI: 214.9, 62.5) compared with 231.0 μmol/L (95{\%} CI: 266.4, 4.2); P = 0.04). There was no effect from zinc supplementation on osteocalcin, ICTP, pyridinoline, deoxypyridinoline, or IGF-I. There was no moderation by race, BMI classification, or plasma zinc status at baseline. Conclusions: Our data suggest that 4 wk of zinc supplementation increases bone formation in premenarcheal girls. Further studies are needed to determine whether supplemental zinc can improve childhood bone strength. This trial was registered at clinicaltrials.gov as NCT01892098.",
keywords = "Bone, Bone turnover, Children, Growth, Zinc",
author = "Berger, {Paige K.} and Pollock, {Norman K.} and Laing, {Emma M.} and Valerie Chertin and Bernard, {Paul J.} and Arthur Grider and Shapses, {Sue A.} and Kehong Ding and Isales, {Carlos M} and Lewis, {Richard D.}",
year = "2015",
month = "1",
day = "1",
doi = "10.3945/jn.115.218792",
language = "English (US)",
volume = "145",
pages = "2699--2704",
journal = "Journal of Nutrition",
issn = "0022-3166",
publisher = "American Society for Nutrition",
number = "12",

}

TY - JOUR

T1 - Zinc supplementation increases procollagen type 1 amino-terminal propeptide in premenarcheal girls

T2 - A randomized controlled trial

AU - Berger, Paige K.

AU - Pollock, Norman K.

AU - Laing, Emma M.

AU - Chertin, Valerie

AU - Bernard, Paul J.

AU - Grider, Arthur

AU - Shapses, Sue A.

AU - Ding, Kehong

AU - Isales, Carlos M

AU - Lewis, Richard D.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Background: Data have shown that healthy children and adolescents have an inadequate intake of zinc, an essential nutrient for growth. It is unclear whether zinc supplementation can enhance bone health during this rapid period of growth and development. Objective: The primary aim of this study was to determine the effect of zinc supplementation on biochemical markers of bone turnover and growth in girls entering the early stages of puberty. The secondary aim was to test moderation by race, body mass index (BMI) classification, and plasma zinc status at baseline. Methods: One hundred forty seven girls aged 9-11 y (46% black) were randomly assigned to a daily oral zinc tablet (9 mg elemental zinc; n = 75) or an identical placebo (n = 72) for 4 wk. Fasting plasma zinc, procollagen type 1 amino-terminal propeptide (P1NP; a bone formation marker), carboxy-terminal telopeptide region of type 1 collagen (ICTP; a bone resorption marker), and insulin-like growth factor I (IGF-I) were assessed at baseline and post-test. Additional markers of bone formation (osteocalcin) and resorption (urinary pyridinoline and deoxypyridinoline) were also measured. Results: Four weeks of zinc supplementation increased plasma zinc concentrations compared with placebo [mean change, 1.8 μmol/L (95% CI: 1.0, 2.6) compared with 0.2 μmol/L (95% CI: 20.3, 0.7); P < 0.01]. Zinc supplementation also increased serum P1NP concentrations compared with placebo [mean change, 23.8 μmol/L (95% CI: 214.9, 62.5) compared with 231.0 μmol/L (95% CI: 266.4, 4.2); P = 0.04). There was no effect from zinc supplementation on osteocalcin, ICTP, pyridinoline, deoxypyridinoline, or IGF-I. There was no moderation by race, BMI classification, or plasma zinc status at baseline. Conclusions: Our data suggest that 4 wk of zinc supplementation increases bone formation in premenarcheal girls. Further studies are needed to determine whether supplemental zinc can improve childhood bone strength. This trial was registered at clinicaltrials.gov as NCT01892098.

AB - Background: Data have shown that healthy children and adolescents have an inadequate intake of zinc, an essential nutrient for growth. It is unclear whether zinc supplementation can enhance bone health during this rapid period of growth and development. Objective: The primary aim of this study was to determine the effect of zinc supplementation on biochemical markers of bone turnover and growth in girls entering the early stages of puberty. The secondary aim was to test moderation by race, body mass index (BMI) classification, and plasma zinc status at baseline. Methods: One hundred forty seven girls aged 9-11 y (46% black) were randomly assigned to a daily oral zinc tablet (9 mg elemental zinc; n = 75) or an identical placebo (n = 72) for 4 wk. Fasting plasma zinc, procollagen type 1 amino-terminal propeptide (P1NP; a bone formation marker), carboxy-terminal telopeptide region of type 1 collagen (ICTP; a bone resorption marker), and insulin-like growth factor I (IGF-I) were assessed at baseline and post-test. Additional markers of bone formation (osteocalcin) and resorption (urinary pyridinoline and deoxypyridinoline) were also measured. Results: Four weeks of zinc supplementation increased plasma zinc concentrations compared with placebo [mean change, 1.8 μmol/L (95% CI: 1.0, 2.6) compared with 0.2 μmol/L (95% CI: 20.3, 0.7); P < 0.01]. Zinc supplementation also increased serum P1NP concentrations compared with placebo [mean change, 23.8 μmol/L (95% CI: 214.9, 62.5) compared with 231.0 μmol/L (95% CI: 266.4, 4.2); P = 0.04). There was no effect from zinc supplementation on osteocalcin, ICTP, pyridinoline, deoxypyridinoline, or IGF-I. There was no moderation by race, BMI classification, or plasma zinc status at baseline. Conclusions: Our data suggest that 4 wk of zinc supplementation increases bone formation in premenarcheal girls. Further studies are needed to determine whether supplemental zinc can improve childhood bone strength. This trial was registered at clinicaltrials.gov as NCT01892098.

KW - Bone

KW - Bone turnover

KW - Children

KW - Growth

KW - Zinc

UR - http://www.scopus.com/inward/record.url?scp=84951127310&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84951127310&partnerID=8YFLogxK

U2 - 10.3945/jn.115.218792

DO - 10.3945/jn.115.218792

M3 - Article

C2 - 26491117

AN - SCOPUS:84951127310

VL - 145

SP - 2699

EP - 2704

JO - Journal of Nutrition

JF - Journal of Nutrition

SN - 0022-3166

IS - 12

ER -